NASDAQ:FENC - Fennec Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $9.68 -0.13 (-1.33 %) (As of 07/15/2018 04:00 PM ET)Previous Close$9.68Today's Range$9.63 - $9.816752-Week Range$7.55 - $14.99Volume29,894 shsAverage Volume161,728 shsMarket Capitalization$179.84 millionP/E RatioN/ADividend YieldN/ABeta-0.24 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina. Receive FENC News and Ratings via Email Sign-up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical SymbolNASDAQ:FENC CUSIPN/A Webwww.fennecpharma.com Phone919-636-4530 Debt Debt-to-Equity RatioN/A Current Ratio22.93 Quick Ratio22.93 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$1.68 per share Price / Book5.76 Profitability EPS (Most Recent Fiscal Year)($0.47) Net Income$-7,040,000.00 Net MarginsN/A Return on Equity-44.03% Return on Assets-41.44% Miscellaneous Employees3 Outstanding Shares18,580,000Market Cap$179.84 Fennec Pharmaceuticals (NASDAQ:FENC) Frequently Asked Questions What is Fennec Pharmaceuticals' stock symbol? Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC." How were Fennec Pharmaceuticals' earnings last quarter? Fennec Pharmaceuticals Inc (NASDAQ:FENC) released its quarterly earnings data on Monday, May, 14th. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.12) by $0.03. View Fennec Pharmaceuticals' Earnings History. When is Fennec Pharmaceuticals' next earnings date? Fennec Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, August, 10th 2018. View Earnings Estimates for Fennec Pharmaceuticals. What price target have analysts set for FENC? 3 analysts have issued 1-year price targets for Fennec Pharmaceuticals' shares. Their predictions range from $17.00 to $22.00. On average, they expect Fennec Pharmaceuticals' share price to reach $19.00 in the next twelve months. This suggests a possible upside of 96.3% from the stock's current price. View Analyst Ratings for Fennec Pharmaceuticals. What is the consensus analysts' recommendation for Fennec Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Fennec Pharmaceuticals stock? Here are some recent quotes from research analysts about Fennec Pharmaceuticals stock: 1. According to Zacks Investment Research, "Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. The Company's products include Eniluracil and Sodium Thiosulfate (STS). Fennec Pharmaceuticals Inc., formerly known as Adherex Technologies Inc., is based in United States. " (5/30/2018) 2. HC Wainwright analysts commented, "We remind investors that Fennec has guided towards the completion of the New Drug Application (NDA) submission to the FDA by late this year. In addition, we note that the agency previously granted PEDMARK (a unique formulation of sodium thiosulfate) the prized Breakthrough Therapy Designation (BTD) for prevention of cisplatin-related ototoxicity in pediatric patients with standard risk hepatoblastoma (SR-HB). There are currently no drugs approved in the U.S. for this condition. BTD is intended to facilitate development and expedite review of drugs to treat serious and life-threatening conditions for which there are no existing effective therapies. Given its Orphan Drug classification, BTD and Fast Track status, along with the unmet need in the pediatric oncology patient population, we continue to believe that PEDMARK could be approved in mid-2019 and launched in the U.S." (5/23/2018) Who are some of Fennec Pharmaceuticals' key competitors? Some companies that are related to Fennec Pharmaceuticals include Avrobio (AVRO), CASI Pharmaceuticals (CASI), Fate Therapeutics (FATE), BioCryst Pharmaceuticals (BCRX), Voyager Therapeutics (VYGR), Nightstar Therapeutics (NITE), Translate Bio (TBIO), Mesoblast (MESO), Novavax (NVAX), Surface Oncology (SURF), PDL BioPharma (PDLI), NanoString Technologies (NSTG), Scholar Rock (SRRK), Osiris Therapeutics (OSIR) and Cellular Biomedicine Group (CBMG). Who are Fennec Pharmaceuticals' key executives? Fennec Pharmaceuticals' management team includes the folowing people: Mr. Rostislav Raykov, Pres, CEO & Director (Age 42)Mr. Robert C. Andrade, Chief Financial Officer (Age 43)Mr. Mark Gowland, ControllerMr. Lei Fang, Pres of Pharstat IncMs. Anne McKay, Regulatory Consultant (Age 64) Has Fennec Pharmaceuticals been receiving favorable news coverage? Press coverage about FENC stock has trended somewhat positive recently, according to Accern. Accern identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Fennec Pharmaceuticals earned a media sentiment score of 0.09 on Accern's scale. They also assigned media coverage about the company an impact score of 45.51 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. How do I buy shares of Fennec Pharmaceuticals? Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Fennec Pharmaceuticals' stock price today? One share of FENC stock can currently be purchased for approximately $9.68. How big of a company is Fennec Pharmaceuticals? Fennec Pharmaceuticals has a market capitalization of $179.84 million. The company earns $-7,040,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Fennec Pharmaceuticals employs 3 workers across the globe. How can I contact Fennec Pharmaceuticals? Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530. MarketBeat Community Rating for Fennec Pharmaceuticals (NASDAQ FENC)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 51 (Vote Outperform)Underperform Votes: 48 (Vote Underperform)Total Votes: 99MarketBeat's community ratings are surveys of what our community members think about Fennec Pharmaceuticals and other stocks. Vote "Outperform" if you believe FENC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FENC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/15/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?